SLZ Stock Overview A biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. More details
Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Enveric Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Enveric Biosciences Historical stock prices Current Share Price US$4.67 52 Week High US$35.62 52 Week Low US$4.27 Beta 0.28 1 Month Change -3.41% 3 Month Change -29.76% 1 Year Change -52.66% 3 Year Change -98.93% 5 Year Change n/a Change since IPO -99.79%
Recent News & Updates Enveric Biosciences, Inc. has filed a Follow-on Equity Offering. Jan 15
Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior Nov 26
The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences Nov 24
The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences Nov 23
New major risk - Financial position Nov 17
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 Oct 15 See more updates Enveric Biosciences, Inc. has filed a Follow-on Equity Offering. Jan 15
Enveric Biosciences Announces Completion of Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior Nov 26
The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences Nov 24
The Listing Qualifications Department of the Nasdaq Stock Market Issues A Determination to Enveric Biosciences Nov 23
New major risk - Financial position Nov 17
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003 Oct 15
New major risk - Financial position Aug 01
Enveric Biosciences Announces Preclinical Results Confirming Potential of EB-003 to Be Dosed Orally Jul 26
New major risk - Share price stability Jul 24
Enveric Biosciences Regains Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Listing Rule 5550(b)(1) May 25
Enveric Biosciences Receives Notification Letter from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement for Continued Listing on the Nasdaq Capital Market Pursuant to Nasdaq Marketplace Rule 5550(a)(2) May 18
New major risk - Financial position May 17
High number of new and inexperienced directors Apr 25
Enveric Biosciences, Inc., Annual General Meeting, May 28, 2024 Apr 17
New major risk - Shareholder dilution Mar 12 Enveric Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $0.322453 million. Mar 11
Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders Feb 22
Enveric Biosciences Receives Notice from the Nasdaq Stock Market Feb 09
New major risk - Share price stability Feb 03
Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series Dec 28
Enveric Biosciences Selects Development Candidates from Evm301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds Dec 06
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry Nov 29
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal Chemistry Nov 28
Enveric Biosciences Receives a Deficiency Letter from the Listing Qualifications Department of the Nasdaq Stock Market Nov 23
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373 Oct 19
Enveric Biosciences, Inc., Annual General Meeting, Nov 02, 2023 Sep 19
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program Aug 22
High number of new and inexperienced directors Aug 21
Enveric Biosciences, Inc. Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 Jul 25
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 Jul 18
Enveric Biosciences, Inc. Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up Manufacturing Jun 28
Enveric Biosciences, Inc. Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders May 24
Enveric Biosciences, Inc. Receives Notice of Allowance from Uspto for Novel Prodrug of Psilocin May 19
High number of new and inexperienced directors Mar 03
High number of new and inexperienced directors Nov 21
Enveric Biosciences, Inc. Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies Oct 25
Enveric Biosciences, Inc., Annual General Meeting, Oct 28, 2022 Sep 24
Enveric Biosciences, Inc. Appoints Robert Dickey IV as Chief Financial Officer Sep 14
Enveric Biosciences, Inc. Regains Compliance with Listing Rule 5550(a)(2) Letter from the Listing Qualifications Department of Nasdaq Aug 03 Enveric Biosciences, Inc. Appoints New Independent Directors Enveric Biosciences, Inc. announced that it expects to receive $5 million in funding Jul 26
Enveric Biosciences Announces Formation of Scientific Advisory Board to Drive Further Growth of Next-Generation Mental Health Medicines Jul 20
Enveric Biosciences, Inc. Announces Appointment of Frank Pasqualone to the Board of Directors Jul 19
Enveric Biosciences Announces Management Appointments Jun 16
High number of new and inexperienced directors Apr 28
Enveric Biosciences, Inc. Expands Portfolio of Drug Development Candidates and Files New Provisional Patent Application Mar 30
Enveric Biosciences Files Portfolio of Patent Applications for Tryptamine-Based Molecules Mar 03
Enveric Biosciences, Inc. announces development of EV104a and EV104b Feb 09
Enveric Biosciences, Inc. (NasdaqCM:ENVB) entered into a definitive agreement to acquire MagicMed Industries Inc. May 25
Enveric Biosciences, Inc. announced delayed annual 10-K filing Apr 03
Enveric Biosciences, Inc. Appoints Dr. Douglas D. Lind to Company's Board of Directors Mar 19
Enveric Biosciences, Inc. (NasdaqCM:ENVB) completed the acquisition of Exclusive and perpetual license for Diverse Biotech novel molecules from Diverse Biotech, Inc. Mar 17 Shareholder Returns SLZ DE Pharmaceuticals DE Market 7D -1.4% 2.6% 1.9% 1Y -52.7% -9.1% 14.1%
See full shareholder returns
Return vs Market: SLZ underperformed the German Market which returned 14.1% over the past year.
Price Volatility Is SLZ's price volatile compared to industry and market? SLZ volatility SLZ Average Weekly Movement 15.0% Pharmaceuticals Industry Average Movement 5.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.0% 10% least volatile stocks in DE Market 2.5%
Stable Share Price: SLZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: SLZ's weekly volatility has decreased from 33% to 15% over the past year, but is still higher than 75% of German stocks.
About the Company Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer.
Show more Enveric Biosciences, Inc. Fundamentals Summary How do Enveric Biosciences's earnings and revenue compare to its market cap? SLZ fundamental statistics Market cap €2.80m Earnings (TTM ) -€9.48m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) SLZ income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$9.86m Earnings -US$9.86m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/30 00:06 End of Day Share Price 2025/01/24 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Enveric Biosciences, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Nathan Weinstein Aegis Capital Corporation James Molloy Alliance Global Partners Hunter Diamond Diamond Equity Research LLC
Show 2 more analysts 